NYC’s low coronavirus rates due to masks, social distancing: Councilman
NYC councilman Stephen Levin argues slowing down the reopening process is the right decision for New York City because ‘we want to protect what we have right now,’ pointing to the city’s current low coronavirus rates.
(Reuters) – Regeneron Pharmaceuticals Inc said on Monday it began late-stage clinical trials to assess the effectiveness of its antibody cocktail in preventing and treating COVID-19, sending its shares up nearly 4%.
Continue Reading Below
The trial, run jointly with the National Institute of Allergy and Infectious Diseases (NIAID), would test REGN-COV2's ability to prevent infection in those who have had close exposure to a COVID-19 patient.
REGN-COV2, an experimental therapy, has also entered into mid-to-late stage phase of two trials testing its effectiveness in hospitalized and non-hospitalized COVID-19 patients, Regeneron said.
WHAT IS REGENERON?
Regeneron is among the few front-runners who have begun human trials testing their experimental therapies to fight COVID-19, including Gilead Sciences, Eli Lilly and AbbVie.
|REGN||REGENERON PHARMACEUTICALS INC.||622.45||+13.28||+2.18%|
Regeneron in June began human trial of the antibody cocktail as a treatment for COVID-19, with an "adaptive" design to quickly move to include thousands of patients.
The late-stage trial will be conducted across 100 sites and expected to enroll 2,000 patients in the U.S. It follows a safety assessment of the cocktail in an early-stage trial by an independent committee.
CASINO EXEC DIES IN JULY 4 WATERCRAFT ACCIDENT
Antibodies are proteins made by the body's immune system that recognize, bind and neutralize an invading virus.